Does Wegovy cause loose skin, and what can you do about it?

Does Wegovy itself damage skin, or is it the weight loss doing the work?

This distinction matters. Semaglutide does not directly affect skin structure or collagen production. What changes the skin is the loss of subcutaneous fat, the fatty layer that sits just beneath the dermis and gives skin its 'fill'. When that layer shrinks, skin that has been stretched over months or years may not spring back completely. Wegovy produces, on average, around 15% body-weight reduction over 68 weeks according to the STEP 1 trial published in the New England Journal of Medicine. For someone starting at 110 kg, that could mean losing 16–17 kg, meaningful enough that skin adaptation becomes a genuine consideration, and our page on what Wegovy causes explores how to distinguish the medicine's direct effects from those driven by the weight loss itself.

It is also worth noting that loose or excess skin is not unique to GLP-1 medicines. Anyone who loses a large amount of weight through any means (bariatric surgery, diet alone, or pharmacotherapy) faces the same underlying biology. The question is whether the pace and degree of loss outrun the skin's capacity to adjust. You can read more about the specific mechanisms involved on our dedicated loose skin and Wegovy page.

Who is most likely to notice loose skin after losing weight on Wegovy?

Skin elasticity is largely governed by collagen and elastin, proteins whose production slows with age. Someone in their fifties who loses 20 kg will typically see more visible skin laxity than a thirty-year-old losing the same amount. That is not a reason to avoid treatment; it is just a realistic part of the picture a clinician and patient should discuss together.

Other factors that reduce skin's ability to retract include a long history of carrying excess weight (which overstretches collagen fibres over time), significant prior weight fluctuations, smoking (which impairs collagen synthesis), and sun damage. The area of the body matters too: the abdomen, inner arms and inner thighs tend to be most affected, while the face is sometimes a concern, people occasionally describe a 'deflated' appearance around the cheeks and jaw when weight comes off quickly. If you are curious about other ways semaglutide can affect the skin, our page on Wegovy and dry skin covers a separate but related set of questions.

The pace of loss plays a role as well. Wegovy's graduated dose schedule (starting low and titrating upward) tends to produce a more measured trajectory than, say, a very-low-calorie diet. That slower arc gives skin slightly more time to adapt, though it does not eliminate laxity when total loss is large.

What can you do to reduce the risk of loose skin while on Wegovy?

There is no guaranteed method, but several evidence-informed approaches are worth building into daily life. Resistance training is near the top of the list. Muscle mass supports the skin from beneath and helps maintain a more toned silhouette even as fat reduces. A common mistake is treating a GLP-1 medicine as a reason to move less, if anything, the opposite applies. Muscle also helps preserve metabolic rate during calorie restriction.

Protein intake deserves attention too. When appetite is reduced on semaglutide, the risk of under-eating protein rises. Protein provides amino acids that are the raw material for collagen repair; many clinicians suggest prioritising protein at each meal, even if overall portions are small. Hydration supports skin turgor, plain water rather than anything fancy. Avoiding smoking, if relevant, is one of the single highest-impact changes for connective tissue health generally.

If you are already planning your Wegovy journey and want a structured approach to minimising skin laxity, our prevention guide goes into practical detail. For context on what Wegovy costs as a private prescription, our Wegovy prices page sets out the market picture honestly.

When should you speak to a clinician about skin changes?

Most skin laxity after weight loss is a cosmetic concern rather than a medical one, but there are situations that warrant clinical attention. A skin rash, persistent itching, redness or any skin reaction that develops after starting Wegovy is different from simple laxity and should be assessed promptly, our Wegovy and skin rash page covers that separately. If skin folds become uncomfortable or prone to friction and irritation, that is worth mentioning to your prescriber at a review, as it can affect quality of life and occasionally skin integrity.

The question of whether surgical skin removal (such as an abdominoplasty) might eventually be appropriate is one a plastic surgeon would assess after weight has been stable for a sustained period. That conversation sits well outside the scope of a weight-loss prescription but is a real option some people explore after major loss. For general questions about our clinical team and how prescriber reviews work at nume, the clinical team profile gives a clearer picture of who is reviewing your care.

A question our prescribers hear regularly is whether loose skin means treatment has 'gone wrong'. It has not. It is a predictable consequence of meaningful weight loss, the kind that improves blood pressure, reduces joint load and lowers metabolic risk. The NHS semaglutide information page focuses on side effects in the clinical sense; skin laxity does not appear there because it is not a pharmacological effect of the medicine. That framing can be reassuring, even if the cosmetic reality still needs managing. If you have questions about your individual situation, our prescribers are available seven days a week, start with a free consultation and take it from there.